Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Meth Abuse Education Program To Begin Regionally, CHPA Says

This article was originally published in The Tan Sheet

Executive Summary

A Consumer Healthcare Products Association-sponsored program to educate teenagers about the dangers of methamphetamine abuse should commence regionally in Atlanta, St. Louis and San Diego at the end of the year or in early 2002 and will eventually expand nationwide.

You may also be interested in...



Pseudoephedrine

Amended bill restricting pseudoephedrine-containing OTC sales to three packages per transaction is before Arkansas Senate Judiciary Committee following House passage March 12. The bill, HB 1417, also would make it illegal to sell such products to anyone under 18. CHPA had opposed an earlier version of the bill, which would have classified pseudoephedrine as a Schedule V substance to be dispensed only under direct pharmacist supervision (1"The Tan Sheet" Feb. 26, In Brief). Similar legislation restricting the quantity of pseudoephedrine that may be purchased in a single transaction is being considered in Missouri (SB 608) and Washington (SB 5017)

CHPA/Nevada AG Meth Retail Education Poster Campaign Under Way

Unusually large retail purchases of OTC cold, allergy, sinus and asthma medicines may signify the items are being used to produce methamphetamine in an illegal lab, recently distributed posters warn retail store clerks.

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS092313

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel